Exploration of Targeted Anti-tumor Therapy

Open Access Review

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?

Marta Nerone ... Ilaria Colombo

Published: April 19, 2022 Explor Target Antitumor Ther. 2022;3:149–171

DOI: https://doi.org/10.37349/etat.2022.00077

This article belongs to the special issue Antibody-Drug Conjugates

Full Text PDF

11316 157 10

Open Access Review

Yeast as a tool to decipher the molecular mechanisms underlying the functions of Bcl-2 family

Stéphen Manon

Published: April 02, 2022 Explor Target Antitumor Ther. 2022;3:128–148

DOI: https://doi.org/10.37349/etat.2022.00076

This article belongs to the special issue The Role of Bcl-2 Family Proteins in Cancer Progression and Their Relevance to Cancer Therapy

Full Text PDF

5862 51 9

Open Access Review

Polyester materials for mRNA delivery

Wang Chen ... Dandan Zhu

Published: March 11, 2022 Explor Target Antitumor Ther. 2022;3:117–127

DOI: https://doi.org/10.37349/etat.2022.00075

This article belongs to the special issue Gene Delivery Approach to Fight Cancer

Full Text PDF

6555 141 9

Open Access Original Article

Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

Kate M. Moore ... Simon P. Langdon

Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:97–116

DOI: https://doi.org/10.37349/etat.2022.00074

This article belongs to the special issue Endocrine Resistant Breast Cancer

Full Text PDF

4748 73 1

Open Access Case Report

Liver venous deprivation for resection of advanced hilar cholangiocarcinoma—a case report and review of the literature

Radoslava Stoyanova ... Alexander Klaus

Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:90–96

DOI: https://doi.org/10.37349/etat.2022.00073

This article belongs to the special issue Precision Medicine for Cholangiocarcinoma

Full Text PDF

4382 55 2

Open Access Review

Targeting the two-pore channel 2 in cancer progression and metastasis

Kathryn A. Skelding ... Lisa F. Lincz

Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:62–89

DOI: https://doi.org/10.37349/etat.2022.00072

This article belongs to the special issue Calcium Signaling Apparatus in Cancers

Full Text PDF

7972 85 13

Open Access Review

Engineered phosphorus dendrimers as powerful non-viral nanoplatforms for gene delivery: a great hope for the future of cancer therapeutics

Serge Mignani ... Jean-Pierre Majoral

Published: February 25, 2022 Explor Target Antitumor Ther. 2022;3:50–61

DOI: https://doi.org/10.37349/etat.2022.00071

This article belongs to the special issue Gene Delivery Approach to Fight Cancer

Full Text PDF

4858 54 6

Open Access Original Article

B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells

Annabel R. Minton ... Graham Packham

Published: February 25, 2022 Explor Target Antitumor Ther. 2022;3:37–49

DOI: https://doi.org/10.37349/etat.2022.00070

Full Text PDF

6818 85 4

Open Access Review

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

Kira-Lee Koster ... Markus Joerger

Published: February 24, 2022 Explor Target Antitumor Ther. 2022;3:27–36

DOI: https://doi.org/10.37349/etat.2022.00069

This article belongs to the special issue Antibody-Drug Conjugates

Full Text PDF

9231 108 28

Open Access Original Article

Bcl-2-like protein-10 increases aggressive features of melanoma cells

Donatella Del Bufalo ... Simona D’Aguanno

Published: January 30, 2022 Explor Target Antitumor Ther. 2022;3:11–26

DOI: https://doi.org/10.37349/etat.2022.00068

This article belongs to the special issue The Role of Bcl-2 Family Proteins in Cancer Progression and Their Relevance to Cancer Therapy

Full Text PDF

5947 80 8

Open Access Review

Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?

Monique Hartley-Brown, Paul Richardson

Published: January 14, 2022 Explor Target Antitumor Ther. 2022;3:1–10

DOI: https://doi.org/10.37349/etat.2022.00067

This article belongs to the special issue Antibody-Drug Conjugates

Full Text PDF

8818 143 9

Open Access Review

Interface between obesity with dysfunctional metabolism and inflammation, and the triple-negative breast cancer in African American women

Katarzyna Rygiel

Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:602–616

DOI: https://doi.org/10.37349/etat.2021.00066

This article belongs to the special issue Endocrine Resistant Breast Cancer

Full Text PDF

4668 62 1

Open Access Original Article

The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type

Chiara Tarantelli ... Francesco Bertoni

Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:586–601

DOI: https://doi.org/10.37349/etat.2021.00065

This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)

Full Text PDF

7391 119 7

Open Access Original Article

Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates

Tomohiro Fujii ... Yutaka Matsuda

Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:576–585

DOI: https://doi.org/10.37349/etat.2021.00064

This article belongs to the special issue Antibody-Drug Conjugates

Full Text PDF

9431 248 13

Open Access Original Article

Alterations in the Ca²⁺ toolkit in oesophageal adenocarcinoma

Alana L. Cutliffe ... John J. Mackrill

Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:543–575

DOI: https://doi.org/10.37349/etat.2021.00063

This article belongs to the special issue Calcium Signaling Apparatus in Cancers

Full Text PDF

6373 62 4

Open Access Review

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies

Stefano Cavalieri ... Laura D. Locati

Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:522–542

DOI: https://doi.org/10.37349/etat.2021.00062

This article belongs to the special issue Immunotherapy in Cancer Patients

Full Text PDF

7168 108 13

Open Access Review

The clinical advances of proteolysis targeting chimeras in oncology

Hao Xie ... Jason B. Fleming

Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511–521

DOI: https://doi.org/10.37349/etat.2021.00061

This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)

Full Text PDF

12708 257 33

Open Access Review

Proteolysis-targeting chimeras and their implications in breast cancer

Angeles C. Tecalco-Cruz ... Alberto Rojas-Ochoa

Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:496–510

DOI: https://doi.org/10.37349/etat.2021.00060

This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)

Full Text PDF

7440 105 10

Open Access Review

Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer

Alfredo Rossi ... Marta Carlesimo

Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:490–495

DOI: https://doi.org/10.37349/etat.2021.00059

This article belongs to the special issue Endocrine Resistant Breast Cancer

Full Text PDF

7252 45 5

Open Access Original Article

Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center

Maristella Bungaro ... Silvia Novello

Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:481–489

DOI: https://doi.org/10.37349/etat.2021.00058

This article belongs to the special issue COVID-19 and Cancer

Full Text PDF

3825 35 0